top of page
Clinical Trial
Invex Therapeutics IIH EVOLVE Phase III Clinical Study
Randomised, placebo-controlled, double-blind Phase III clinical trial that will randomise 240 adult patients with newly diagnosed IIH with papilloedema to determine the efficacy and safety of Presendin versus placebo, administered once weekly over 24 weeks
Enrolling now, but accessible only to patients in Auckland. Talk to your Neuro-Ophthalmologist.
Future Trials in the pipeline 2023/2024....
bottom of page